SCHEMBL29776573

SCHEMBL29776573

O=C1Nc2cc(Cl)ccc2/C1=C\c1cccc(Cl)c1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 2/20 0.53
▸ TUBB4A P04350 2/20 0.49
▸ TUBB P07437 2/20 0.49
▸ TUBA3C P0DPH7 2/20 0.49
▸ TUBA1B P68363 2/20 0.49
▸ TUBA4A P68366 2/20 0.49
▸ TUBB4B P68371 2/20 0.49
▸ TUBB3 Q13509 2/20 0.49
▸ TUBB2A Q13885 2/20 0.49
▸ TUBB8 Q3ZCM7 2/20 0.49
▸ TUBA3E Q6PEY2 2/20 0.49
▸ TUBA1A Q71U36 2/20 0.49
▸ TUBA1C Q9BQE3 2/20 0.49
▸ TUBB6 Q9BUF5 2/20 0.49
▸ TUBB2B Q9BVA1 2/20 0.49
▸ TUBB1 Q9H4B7 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ LRRK2 Q5S007 2/20 0.47
▸ CES1 P23141 1/20 0.47
▸ PDGFRB P09619 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL250345 1.00 MDM2 (0.53) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29443894 1.00 MDM2 (0.53) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL223844 1.00 MDM2 (0.53) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29875754 0.90 LRRK2 (0.60) MDM2LRRK2PDGFRBCDK2TGM2
SCHEMBL28711339 0.90 LRRK2 (0.60) MDM2LRRK2PDGFRBCDK2TGM2
SCHEMBL14659628 0.90 NPC1 (0.56) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14659629 0.90 NPC1 (0.56) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2739255 0.88 NPC1 (0.47) MDM2NPC1PDGFRBTGM2MEN1
SCHEMBL14658998 0.88 MEN1 (0.52) MDM2NPC1PDGFRBMEN1KMT2A
SCHEMBL6822268 0.88 NPC1 (0.47) MDM2NPC1PDGFRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4447959-A1 METHODS OF TREATING CANCER Kymera Therapeutics, Inc. (US) 2024-10-23 — — EP disclosed
CN-118574613-A Methods of treating cancer 凯麦拉医疗公司 2024-08-30 — — CN disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 — — EP disclosed
WO-2023114933-A1 METHODS OF TREATING CANCER KYMERA THERAPEUTICS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 — — WO disclosed
CN-115776887-A MDM2 degrading agents and uses thereof 凯麦拉医疗公司 2023-03-10 — — CN disclosed
EP-4121043-A1 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
CN-113387957-B Spirocyclic indolone-pyrrolidine carbonate compound and composition, preparation method and application thereof 江苏亚尧生物科技有限公司 2022-08-09 — — CN disclosed
Send feedback